EUVIMEDEUVIMED entdecken
Open Access

Tecovirimat Resistance in Mpox Patients, United States, 2022–2023

Todd G Smith, Crystal M Gigante, Nhien T Wynn, Audrey Matheny, Whitni Davidson, Yong Yang, Rene Edgar Condori, Kyle O'Connell, Lynsey Kovar, Tracie L Williams, Yon C Yu, Brett W Petersen und 5 weitere

Emerging Infectious Diseases · 2023-12 · 29 (12)

DOI: 10.3201/eid2912.231146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Emerging Infectious Diseases, 2023-12. Verfasst von Todd G Smith und 16 weiteren Autor:innen. Hauptthemen laut MEDLINE: Mpox, Monkeypox. Die Arbeit wurde bisher 133-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

During the 2022 multinational outbreak of monkeypox virus (MPXV) infection, the antiviral drug tecovirimat (TPOXX; SIGA Technologies, Inc., https://www.siga.com) was deployed in the United States on a large scale for the first time. The MPXV F13L gene homologue encodes the target of tecovirimat, and single amino acid changes in F13 are known to cause resistance to tecovirimat. Genomic sequencing identified 11 mutations previously reported to cause resistance, along with 13 novel mutations. Resistant phenotype was determined using a viral cytopathic effect assay. We tested 124 isolates from 68 patients; 96 isolates from 46 patients were found to have a resistant phenotype. Most resistant isolates were associated with severely immunocompromised mpox patients on multiple courses of tecovirimat treatment, whereas most isolates identified by routine surveillance of patients not treated with tecovirimat remained sensitive. The frequency of resistant viruses remains relatively low (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mpox, MonkeypoxHumansUnited StatesAntiviral AgentsBenzamidesBiological AssayMonkeypox virus

Stichwörter der Autor:innen

ST-246TPOXXUnited Statesantimicrobial resistanceantiviralsmonkeypox virusmpoxorthopoxvirustecovirimatviruses

Substanzen

Antiviral AgentsBenzamides

Zitieren

APA

Smith, T. G., Gigante, C. M., Wynn, N. T., Matheny, A., Davidson, W., Yang, Y., Condori, R. E., O'Connell, K., Kovar, L., Williams, T. L., Yu, Y. C., Petersen, B. W., Baird, N., Lowe, D., Li, Y., Satheshkumar, P. S., & Hutson, C. L. (2023). Tecovirimat Resistance in Mpox Patients, United States, 2022–2023. Emerging Infectious Diseases, 29(12). https://doi.org/10.3201/eid2912.231146

Vancouver

Smith TG, Gigante CM, Wynn NT, Matheny A, Davidson W, Yang Y, et al. Tecovirimat Resistance in Mpox Patients, United States, 2022–2023. Emerging Infectious Diseases. 2023;29(12). doi:10.3201/eid2912.231146

BibTeX
@article{Smith2023,
  author = {Smith, Todd G and Gigante, Crystal M and Wynn, Nhien T and Matheny, Audrey and Davidson, Whitni and Yang, Yong and Condori, Rene Edgar and O'Connell, Kyle and Kovar, Lynsey and Williams, Tracie L and Yu, Yon C and Petersen, Brett W and Baird, Nicolle and Lowe, David and Li, Yu and Satheshkumar, Panayampalli S and Hutson, Christina L},
  title = {Tecovirimat Resistance in Mpox Patients, United States, 2022–2023},
  journal = {Emerging Infectious Diseases},
  year = {2023},
  volume = {29},
  number = {12},
  doi = {10.3201/eid2912.231146}
}
Kostenlos starten →